These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38810199)

  • 21. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.
    Hatzaki D; Poulakou G; Katsarolis I; Lambri N; Souli M; Deliolanis I; Nikolopoulos GK; Lebessi E; Giamarellou H
    BMC Infect Dis; 2012 Sep; 12():228. PubMed ID: 23009290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study.
    Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler M; Tolomeo P; Han JH;
    BMC Infect Dis; 2019 Feb; 19(1):163. PubMed ID: 30764770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Choice of antibacterial drugs in urinary infection].
    Perepanova TS; Kozlov RS; Dekhnich AV; Palagin IS; Shevelev AN; Volkova EM; Égamberdiev DK
    Urologiia; 2012; (2):4-8. PubMed ID: 22876623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
    McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
    Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The activity of cefetamet against enterobacterial isolates from community-acquired urinary tract infections.
    Sofianou D; Tsakris A; Nikolaidis P; Kotis E; Tourkantonis A
    J Antimicrob Chemother; 1996 Aug; 38(2):320-2. PubMed ID: 8877552
    [No Abstract]   [Full Text] [Related]  

  • 30. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae.
    Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler MK; Tolomeo P; Han JH;
    Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1431-1435. PubMed ID: 30375298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
    Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
    JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of cephalexin monohydrate in patients with uncomplicated urinary infections].
    Todd LE; Sepulveda C
    Prensa Med Mex; 1970; ():69-74. PubMed ID: 4931121
    [No Abstract]   [Full Text] [Related]  

  • 34. Cephalexin monohydrate in the treatment of urinary tract infections and urethritis.
    Rocha H; Peltier Queiroz F
    Prensa Med Mex; 1970; ():56-60. PubMed ID: 4931118
    [No Abstract]   [Full Text] [Related]  

  • 35. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function.
    Maganti R; Jolin D; Rishi D; Biswas A
    Epilepsy Behav; 2006 Feb; 8(1):312-4. PubMed ID: 16278098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Profile of antimicrobial resistance of agents causing urinary tract infections in children].
    Ghedira Besbes L; Messaoudi A; Ben Meriem C; Guediche MN
    Tunis Med; 2004 Mar; 82(3):299-305. PubMed ID: 15382465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too.
    Altshuler J; Aitken SL; Guervil D; Esaian D; Papadopoulos J; Arias CA
    Clin Infect Dis; 2013 Sep; 57(6):915-6. PubMed ID: 23784927
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic results of cephalexin monohydrate in urinary infections].
    Soto RF; Febres F; Cordidos A; Linares J; Cabrera A
    Prensa Med Mex; 1970; ():51-5. PubMed ID: 4931117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.